Radiation boosts standard therapy in advanced breast cancer trial

NCT ID NCT04563507

Recruiting now Disease control Sponsor: Weill Medical College of Cornell University Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This Phase 2 trial tests whether adding targeted radiation (SBRT) to standard hormone therapy and a CDK4/6 inhibitor can help women with metastatic HR+ HER2- breast cancer live longer without their disease worsening. About 102 participants will be randomly assigned to receive either standard therapy alone or standard therapy plus SBRT to each metastatic lesion. The study is currently recruiting.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Stereotactic Body Radiation Therapy (SBRT)
What this could lead to: If successful, adding SBRT to standard hormone therapy and CDK4/6 inhibitors could delay cancer progression in women with metastatic breast cancer.
What could go wrong: This is a Phase 2 trial with only 102 participants, so results may not apply to all patients. Radiation side effects and the possibility that the combination offers no added benefit are key risks.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast cancer breast neoplasm hormone receptor-positive breast cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BREAST CANCER

Contacts and locations

Locations

Brooklyn Methodist Hospital - NewYork Presbyterian
RECRUITING

New York, New York, 11215, United States
New York Presbyterian Hospital - Queens
RECRUITING

New York, New York, 11355, United States
Weill Cornell Medicine
RECRUITING

New York, New York, 10065, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.